Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H16N2 |
| Molecular Weight | 200.2795 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CN=C(N1)C2CCCC3=CC=CC=C23
InChI
InChIKey=BYJAVTDNIXVSPW-UHFFFAOYSA-N
InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
| Molecular Formula | C13H16N2 |
| Molecular Weight | 200.2795 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095203 Sources: www.ncbi.nlm.nih.gov/pubmed/18259967 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | TYZINE Approved UseTyzine Nasal Solution is indicated for decongestion of nasal and nasopharyngeal mucosa. Launch Date1979 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.218 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
7500 ug single, oral Overdose |
healthy, 16 years |
Other AEs: Sinoatrial node dysfunction... |
0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years Health Status: healthy Age Group: 20 months-2 years Sex: M+F Sources: |
Other AEs: Bradycardia, Hypertension... Other AEs: Bradycardia (2 patients) Sources: Hypertension (1 patient) Gasping (2 patients) |
250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days |
Other AEs: Hypotonia... |
250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days |
Other AEs: Apnea... |
15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
Other AEs: Hypothermia, Bradycardia... Other AEs: Hypothermia (1 patient) Sources: Bradycardia (1 patient) Hypotension (1 patient) Miosis (1 patient) Lethargy (1 patient) Mucous membrane disorder (NOS) (1 patient) Bowel sounds decreased (1 patient) Chest pain (1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Sinoatrial node dysfunction | 1 patient | 7500 ug single, oral Overdose |
healthy, 16 years |
| Hypertension | 1 patient | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years Health Status: healthy Age Group: 20 months-2 years Sex: M+F Sources: |
| Bradycardia | 2 patients | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years Health Status: healthy Age Group: 20 months-2 years Sex: M+F Sources: |
| Gasping | 2 patients | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years Health Status: healthy Age Group: 20 months-2 years Sex: M+F Sources: |
| Hypotonia | 1 patient | 250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days |
| Apnea | 1 patient | 250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days |
| Bowel sounds decreased | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Bradycardia | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Chest pain | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Hypotension | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Hypothermia | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Lethargy | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Miosis | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
| Mucous membrane disorder (NOS) | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tetrahydrozoline (Visine®) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose. | 2011-11 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| 2-(1,2,3,4-Tetra-hydro-1-naphth-yl)imidazolium chloride monohydrate. | 2010-08-18 |
|
| Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication. | 2010-06 |
|
| Development of a multicommutated flow system with chemiluminometric detection for quantification of gentamicin in pharmaceuticals. | 2010 |
|
| Determination of tetrahydrozoline in urine and blood using gas chromatography-mass spectrometry (GC-MS). | 2010 |
|
| A comparative kinetic and mechanistic study between tetrahydrozoline and naphazoline toward photogenerated reactive oxygen species. | 2009-08-28 |
|
| Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. | 2008-02 |
|
| Patient use of Visine (tetrahydrozoline) masks Horner syndrome. | 2008-01 |
|
| Comparative evaluation of antimicrobial efficacy of sodium hypochlorite, MTAD, and Tetraclean against Enterococcus faecalis biofilm. | 2007-07 |
|
| Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine). | 2007-07 |
|
| Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum. | 2006-07 |
|
| [Drug administration in newborns. Is clinical experience enough?]. | 2006-04 |
|
| Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization. | 2006-01 |
|
| Simple HPLC determination of benzalkonium chloride in ophthalmic formulations containing antazoline and tetrahydrozoline. | 2005-12-01 |
|
| [Systemic involvement in premature infants after intranasal administration of tetryzoline drops]. | 2005-10 |
|
| Effects of two eye drop products on computer users with subjective ocular discomfort. | 2005-01 |
|
| Sinoatrial node arrest following tetrahydrozoline ingestion. | 2004-10 |
|
| [Acute exposure to imidazoline derivatives in children]. | 2003-12-20 |
|
| [The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters]. | 2003-11 |
|
| Pediatric Visine (tetrahydrozoline) ingestion: case report and review of imidazoline toxicity. | 2003-08 |
|
| Transdermal penetration of vasoconstrictors--present understanding and assessment of the human epidermal flux and retention of free bases and ion-pairs. | 2003-02 |
|
| Simultaneous determination of ofloxacin, tetrahydrozoline hydrochloride, and prednisolone acetate by high-performance liquid chromatography. | 2002-09 |
|
| Gingival inflammatory response induced by chemical retraction agents in beagle dogs. | 2002-03-13 |
|
| Viability of fibroblasts in cell culture after treatment with different chemical retraction agents. | 2002-01 |
|
| Electron microscopic analysis of the effects of chemical retraction agents on cultured rat keratinocytes. | 2002-01 |
|
| Gingival tissue inflammatory response following treatment with chemical retraction agents in Beagle dogs. | 2001 |
Sample Use Guides
Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Solution: It is recommended that 2 to 4 drops be instilled in each nostril as needed, never more often than every three hours. Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Spray: It is recommended to squeeze quickly and firmly three or four times the spray in each nostril as needed, never more often than every three hours. Children 2 to 6 Years of Age, Tyzine 0.05 % Pediatric Nasal Drops: It is recommended that 2 to 3 drops be instilled in each nostril as needed, and never more often than every three hours.
Route of Administration:
Nasal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6289955
Rat and rabbit aortae were treated with tetrahydrozoline at concentrations from 10(-7) to 10(-5) M to determine the drug relative efficacy. Emax value was 0.51 for the rabbit aortae and 0 for the rat aortae.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:26 GMT 2025
by
admin
on
Mon Mar 31 17:46:26 GMT 2025
|
| Record UNII |
S9U025Y077
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QS01GA02
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-ATC |
R01AB03
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-VATC |
QR01AA06
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-VATC |
QS01GA52
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-VATC |
QR01AB03
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-ATC |
S01GA02
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-ATC |
S01GA52
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
||
|
WHO-ATC |
R01AA06
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
519
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
DB06764
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
3591
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
m10634
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
201-522-3
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
28674
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
TETRAHYDROZOLINE
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
7471
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
84-22-0
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
100000082723
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL1266
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
DTXSID1047861
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
5419
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
S9U025Y077
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
37935
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
S9U025Y077
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
SUB10955MIG
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY | |||
|
C61967
Created by
admin on Mon Mar 31 17:46:26 GMT 2025 , Edited by admin on Mon Mar 31 17:46:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |